12-1-17 SmallCapVoice Interview with Oncolix, Inc. (ONCX)

Michael T. Redman, chief executive officer of Oncolix (OTC: ONCX), called back in to SmallCapVoice.com, Inc. to update the listeners and the Company’s shareholders on the progress the Company has made since our last interview back in September. Most importantly Michael shared that the Financial Industry Regulatory Authority (FINRA) has approved a change in the Company’s stock symbol to ONCX, effective at the opening of trading on November 29, 2017. The ticker symbol change is continued demonstration of progress toward positioning Oncolix as an emerging biopharmaceutical company with a clinical-stage asset. He also touched upon the number one goal for the company and that is to continue to build out the public company infrastructure to fulfill the OTCQB listing requirements and ultimately a NASDAQ listing. He went on to talk about the new independent board meme that just came on in December and what investors can expect from the Company in the very near future.

Oncolix is a clinical-stage biotechnology company developing Prolanta™ for the treatment of ovarian, uterine, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in its first indication, the treatment of ovarian cancer. This Phase 1 clinical trial is currently in progress. Prolanta™ is a prolactin receptor antagonist (or blocker) that has demonstrated efficacy in xenograft models through a unique mechanism of action, autophagy. In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ may be effective in breast, prostate and other cancers. In the current Phase 1 dose-escalation safety trial for the treatment of ovarian cancer, to date there have been no observed serious adverse events and no dose-limiting toxicities. The FDA has approved the designation of Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may result in reduced filing fees (currently $2 million), federal tax credits and marketing exclusivity.

This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.